Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashkan Emadi

Blood

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Blood|October 22, 2024
A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemiaYuchen Liu, Dominique R Bollino, Osman M Bah, et al.
Blood|October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Blood|October 22, 2024
A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemiaYuchen Liu, Dominique R Bollino, Osman M Bah, et al.
Blood|October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Pageof 1